Richard Willson (center) and his team are working to develop a mix-and-read antibody measurement system that uses fluorescent materials to determine the amount of antibody present in a sample. Photo via UH.edu

An engineering project at the University of Houston has been selected to join a $10 million effort to bring biopharmaceutical manufacturing into the future. The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) chose the lab of Richard Willson, Huffington-Woestemeyer Professor of chemical and biomolecular engineering at UH, as one of eight development projects that it will fund.

Willson and his team are working to develop a mix-and-read antibody measurement system that uses fluorescent materials to determine the amount of antibody present in a sample. The funding for this project is $200,000. This is the first grant UH has received from NIIMBL.

“In the course of the manufacturing processes, it's important to know the concentration of antibody in your sample and this measurement needs to be made many times in a typical manufacturing process,” said Willson in a press release. In the realm of fluorescents, he is also working to pioneer the use of glow sticks to detect biothreats for the U.S. Navy. His discoveries include a fluorescent material that emits one color of light when excited with another color of light.

Antibodies are what immune cells produce in response to alien substances such as bacteria and viruses. Lab-made antibodies, called monoclonal antibodies, have been in use since the 1980s. Antibody treatments now account for some of the world’s top-selling drugs.

“The nice thing about this reagent is that it becomes more fluorescent in the presence of antibodies, and you can determine the amount of antibody present in a sample by using it,” said Willson. “Along with our industrial partners Genentech, Agilent and Bristol Myers Squibb, we think that this might be a useful tool for people who do everything from growing the cells that make the antibodies, to determining concentrations of antibody before purifying them.”

Willson’s team also includes Katerina Kourentzi, research associate professor of chemical and biomolecular engineering at UH; Yan Chen, Agilent; Midori Greenwood-Goodwin, Genentech/Roche; and Mathura Raman, Bristol-Myers Squibb.

“One really distinguishing feature of this project is the tight coupling to industry,” said Kourentzi. “We got a lot of guidance from our industrial partners who volunteer to work with us through NIIMBL.” And through that, the technology could make it to the market in record time.

At-home COVID-19 testing is about to get lit. Photo via Getty Images

UH researcher lights up at-home COVID-19 testing with glow-in-the-dark materials

get lit

A Houston-based research team is tapping glow-in-the-dark materials to upgrade at-home rapid COVID-19 testing.

Researchers at the University of Houston have been rethinking the lateral flow assay (LFA) test used for at-home COVID-19 diagnostics. The traditional method indicates the sample's results with colored lines.

“We are making those lines glow-in-the-dark so that they are more detectable, so the sensitivity of the test is better,” says Richard Willson, a professor at the University of Houston, in a UH news release. He previously created a smartphone-based diagnostics app.

Willson's inspiration came from a familiar and nostalgic method — the glow-in-the-dark stars in a child's bedroom. In Willson's case, it was his daughter's bedroom, and within a few days his team of students and postdocs was designing a test featuring glowing nanoparticles made of phosphors.

The team evolved into a spin-off company called Clip Health, originally founded as Luminostics by two of the researchers. The operation is again evolving with new glowing applications.

“In this new development, there are two tricks. First, we use enzymes, proteins that catalyze reactions, to drive reactions that emit light, like a firefly. Second, we attached those light-emitting enzymes onto harmless virus particles, along with antibodies that bind to COVID proteins,” says Willson in the Royal Society of Chemistry’s journal Analyst.

The test now also can be read with a smartphone app. The group is also entertaining additional tests for other diseases.

“This technology can be used for detecting all kinds of other things, including flu and HIV, but also Ebola and biodefense agents, and maybe toxins and environmental contaminants and pesticides in food,” says Willson.

In addition to Willson, the original technology was explained in a paper with co-authors:

  • Katerina Kourentzi, University of Houston research associate professor of chemical and biomolecular engineering
  • Jacinta Conrad, Frank M. Tiller Associate Professor of Chemical and Biomolecular Engineering,
  • UH researchers Maede Chabi, Binh Vu, Kristen Brosamer, Maxwell Smith, and Dimple Chavan

Researcher Richard Willson says he was inspired by the glow-in-the-dark scars on his daughter's bedroom ceiling. Photo via UH.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”

Report: Houston reclaims top 10 ranking among America's best cities

Houston has made a triumphant return to America's 10 best cities for 2026, certifying the city is a cornerstone of the country's growth and economic prosperity.

Houston ranks No. 9 nationwide in the annual "America's Best Cities" report from Canada-based real estate and tourism marketing firm Resonance Consultancy. Each year, the report ranks the relative qualities of livability, cultural "lovability," and economic prosperity in 393 American cities with metropolitan populations of 500,000 or more.

Dallas surpassed H-Town as the No. 8 best city in America, and the Lone Star State boasts a strong presence among the top 25. Austin and San Antonio, respectively, were named the 11th and 24th best American cities this year.

Previously, Houston was dubbed the 13th best American city in 2025, down from its No. 10 ranking in the 2024 report.

Rather than profiling each individual city like in past reports, the 2026 edition focuses on regional and state prosperity. Texas' economic dominance is second only to Florida's, and the state's growth is solidified by the Dallas-Houston-Austin "triangle," where each metro has its own distinct economic identity, but when combined "form one of the most formidable regional economies in the world."

"In our 2026 survey, Dallas ranks third nationally as the place Americans believe offers the best job opportunities, Austin fifth, and Houston seventh," the report's author wrote. "That concentration of perceived economic opportunity in a single state is unmatched, and the GDP data confirms it isn’t just perception."

After being named one of the best places to start a business or a career earlier in 2026, Houston has continued to punch above its weight with its success in tourism, education, and housing growth.

Overall, the report found a correlation between a city's population growth and its latest ranking, with bigger cities appearing higher up on the list. The top three best American cities — New York, Los Angeles, and Chicago — are coincidentally the three largest metros, while Dallas and Houston are the fourth and fifth largest but appear eighth and ninth on the list.

"Scale compounds at the large city level — more people generate more economic activity, more cultural infrastructure, more employer presence, which attracts more people," the report said.

The top 10 best cities in America for 2026 are:

  • No. 1 – New York
  • No. 2 – Los Angeles
  • No. 3 – Chicago
  • No. 4 – Miami
  • No. 5 – San Francisco
  • No. 6 – Seattle
  • No. 7 – Las Vegas
  • No. 8 – Dallas
  • No. 9 – Houston
  • No. 10 – Boston

New probe into Tesla after vehicle slams into Houston-area home at high speed

Tesla Talk

The top U.S. auto regulator opened an investigation Monday, June 22, after a Tesla using an automated driving feature slammed into a Texas home at high speed and killed a 76-year-old woman standing inside.

The National Highway Traffic Safety Administration said it's opening a special investigation into the Tesla Model 3 crash on Friday near Houston, a significant probe because the car was using technology that Elon Musk considers key to the company's future.

The Tesla CEO is rolling out robotaxis using automated software in several U.S. cities this year and plans to invite Tesla owners to put their cars into the fleet using the same system across the country.

The driver told the Harris County Sheriff's Office that he was using the technology, according to a police report on the crash, but it's not clear what role, if any, it played in the incident.

Tesla did not respond to a request for comment but the head of the company's artificial intelligence efforts suggested on social media later Monday that the self-driving feature was not to blame.

“In this case, the driver manually overrode self-driving by pressing the accelerator all the way to 100% of the accel pedal in this residential area,” wrote Ashok Elluswamy on X, the platform that is now part of Musk's rocket company, SpaceX. “They reached a speed of 73 mph during the crash, and had the accelerator pressed even after the crash.”

The police report noted that the driver was not drunk and is cooperating. It identified the woman killed as Martha Avila.

Video obtained by KHOU-TV shows the car traveling at top speed over the front lawn of a brick home in Katy, then ramming into a front room. The next shot shows the car encased in the home amid piles of crumbling plaster, split beams and bits of furniture.

The auto safety regulator, known as NHTSA, has launched several investigations into Tesla, including one late last year into 58 incidents in which Teslas reportedly violated traffic safety laws while using self-driving technology, leading to more than a dozen crashes and fires and nearly two dozen injuries.

A few months earlier, the NHTSA opened an investigation into why Tesla apparently had not been reporting crashes promptly as required.

As for special crash investigations, the NHTSA has opened 46 involving Teslas using self-driving or driver-assistance technology over the past decade, according to the agency's records. In more than a dozen of those crashes, at least one person — a driver, passenger or pedestrian — was killed.

Tesla stock fell sharply early last year as car sales plunged amid a boycott of Musk after he waded into politics, leading President Donald Trump's budget-cutting Department of Government Efficiency initiative and embracing European extremist candidates.

Musk has since shifted the Tesla story to one less about car sales and more about AI and robotaxis, and done so successfully. The stock is up 16% in the past year.